<DOC>
	<DOCNO>NCT00069862</DOCNO>
	<brief_summary>A clinical trial design compare safety iron excretion property desferoxamine ( DFO ) deferitrin ( GT56-252 ) , experimental oral iron chelator .</brief_summary>
	<brief_title>Iron Balance Study DFO GT56-252 Patients With Transfusional Iron Overload Secondary Beta-Thalassemia</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>Betathalassemia patient , 18 year age old , currently undergo chronic blood transfusion therapy iron chelation therapy weigh 40 kg . No clinically significant finding physical exam , medical history , screen laboratory . Serum ferritin great 500 ng/mL , serum creatine creatinine within normal range platelet count great 100,000/mm3 . Willing able discontinue DFO L1 period study . Woman childbearing potential must negative serum pregnancy test screening use medically acceptable form birth control study 1 month afterward . Male patient must also use barrier contraceptive study 1 month afterward . Have level understanding willingness cooperate confinement procedure . Able provide voluntary signed/dated write informed consent . Serious medical condition unrelated BetaThalassemia . Participation previous investigational drug study within 30 day precede screening . Patients know allergy DFO prevents chronic administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Beta Thalassemia</keyword>
</DOC>